Results 51 to 60 of about 1,210,671 (242)
Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display
, 2022 Therapeutic monoclonal antibodies directed against PD-L1 (e.g., atezolizumab) disrupt PD-L1:PD-1 signaling and reactivate exhausted cytotoxic T-cells in the tumor compartment.
Brian J. Grindel (9407114) +10 more
core +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Advanced ScienceImmune checkpoint blockade (ICB) has emerged as a cornerstone of cancer therapy, yet its effectiveness remains restricted in PD‐L1‐low malignancies due to insufficient target expression.
Shaoqing Huang +12 more
doaj +1 more source
Smaller is better: nanobodies meet NMR
FEBS Letters, EarlyView.Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley +1 more source
Current OncologyDurvalumab consolidation after definitive chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC) but real-world data comparing PD-L1-defined subgroups are limited.
Janne Selke +7 more
doaj +1 more source
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Scientific Reports, 2017 In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials.
Hyun Tae Lee +8 more
doaj +1 more source
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Frontiers in Immunology, 2017 PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD-L1 axis is affected by the complex immunologic regulation network, and some
Zijun Y. Xu-Monette +4 more
doaj +1 more source
Cancer Medicine, 2023 Background and Aim Programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors have transformed the treatment landscape of advanced hepatocellular carcinoma (HCC), but consistent responses are not observed in all patients, and prognostic ...
Yao Yang +6 more
doaj +1 more source
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Molecular Oncology, EarlyView.Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley +1 more source
Extracellular vesicles mediate intercellular transfer of PD-L1 and bystander T-cell suppression
Cellular and Molecular Life SciencesExtracellular vesicles (EVs) carrying programmed death-ligand 1(PD-L1) on their membranes regulate immune responses. While membrane PD-L1 can be exchanged between tumor and immune cells through immune synapse, it remains unclear whether PD-L1 exchange ...
Amar Yeware +4 more
doaj +1 more source